MKI67 and neoplasm: While Ki67 staining suggested that there were no differences in 5-day cabozantinib-treated tumors compared to control tumors (percent positive cells = 0.50±0.03 vs 0.50±0.05, p = 0.93, n = 3), proliferation associated pathways such as E2F targets and G2M checkpoint pathways, were decreased in the cabozantinib-treated tumor cells (Fig 5C).